Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro

Allan, E.K., Eaves, C.J., Elliott, M.A., Godden, J.L., Graham, S.M., Holyoake, T.L., Jorgensen, H.G., Mountford, J.C. and Richmond, L. (2005) Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia, 19(7), pp. 1184-1191. (doi:10.1038/sj.leu.2403785)

Full text not currently available from Enlighten.

Abstract

Recent studies indicate that a rare population of primitive quiescent BCR-ABL<sup>+</sup> cells are innately insensitive to imatinib mesylate (IM) and persist after IM therapy of patients with chronic myeloid leukemia (CML). New approaches to the eradication of these cells are therefore likely to be crucial to the development of curative therapies for CML. We have now found that Ara-C, LY294002 (a PI-3 ( phosphatidylinositol-3' kinase) kinase inhibitor), 17AAG (a heat-shock protein (HSP)-90 antagonist) and lonafarnib (a farnesyltransfease inhibitor) all enhance the toxicity of IM on K562 cells and on the total CD34<sup>+</sup> leukemic cell population from chronic phase CML patients. However, for quiescent CD34<sup>+</sup> leukemic cells, this was achieved only by concomitant exposure of the cells to lonafarnib. Ara-C or LY294002 alone blocked the proliferation of these cells but did not kill them, and Ara-C, LY294002 or 17AAG in combination with IM enhanced the cytostatic effect of IM but did not prevent the subsequent regrowth of the surviving leukemic cells. These studies demonstrate the importance of <i>in vitro</i> testing of novel agents on the subset of primary leukemic cells most likely to determine long- term treatment outcomes <i>in vivo</i>.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Holyoake, Professor Tessa and Mountford, Dr Jo and Allan, Mrs Elaine and Jorgensen, Dr Heather
Authors: Allan, E.K., Eaves, C.J., Elliott, M.A., Godden, J.L., Graham, S.M., Holyoake, T.L., Jorgensen, H.G., Mountford, J.C., and Richmond, L.
College/School:College of Arts > School of Critical Studies > Theology and Religious Studies
College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
College of Medical Veterinary and Life Sciences > Institute of Neuroscience and Psychology
Journal Name:Leukemia
ISSN:0887-6924

University Staff: Request a correction | Enlighten Editors: Update this record